[go: up one dir, main page]

BRPI0922867B8 - glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada - Google Patents

glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada

Info

Publication number
BRPI0922867B8
BRPI0922867B8 BRPI0922867A BRPI0922867A BRPI0922867B8 BR PI0922867 B8 BRPI0922867 B8 BR PI0922867B8 BR PI0922867 A BRPI0922867 A BR PI0922867A BR PI0922867 A BRPI0922867 A BR PI0922867A BR PI0922867 B8 BRPI0922867 B8 BR PI0922867B8
Authority
BR
Brazil
Prior art keywords
rsv
respiratory syncytial
syncytial virus
nucleic acid
isolated nucleic
Prior art date
Application number
BRPI0922867A
Other languages
English (en)
Inventor
Zhou Bin
Smith Gale
Massare Michael
Pushko Peter
Liu Ye
Wu Yingyun
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922867(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BRPI0922867A2 publication Critical patent/BRPI0922867A2/pt
Publication of BRPI0922867B1 publication Critical patent/BRPI0922867B1/pt
Publication of BRPI0922867B8 publication Critical patent/BRPI0922867B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

proteína de fusão (f) de vírus sincicial respiratório (rsv), ácido nucléico isolado, composição de vacina, micela purificada, bem como partícula semelhante a um vírus (vlp) a presente invenção refere-se, genericamente, a proteínas de fusão (f) de vírus respiratório sincicial mutadas ou modificadas e os métodos para a fabricação e uso dessas, incluindo composições imunológicas, tais como vacinas para o tratamento e/ou prevenção de infecção por rsv.
BRPI0922867A 2008-12-09 2009-12-09 glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada BRPI0922867B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US61/121,126 2008-12-09
US16907709P 2009-04-14 2009-04-14
US61/169,077 2009-04-14
US22478709P 2009-07-10 2009-07-10
US61/224,787 2009-07-10
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (3)

Publication Number Publication Date
BRPI0922867A2 BRPI0922867A2 (pt) 2016-09-27
BRPI0922867B1 BRPI0922867B1 (pt) 2020-09-29
BRPI0922867B8 true BRPI0922867B8 (pt) 2021-05-25

Family

ID=42310119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922867A BRPI0922867B8 (pt) 2008-12-09 2009-12-09 glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada

Country Status (23)

Country Link
US (7) US8715692B2 (pt)
EP (3) EP3718566B1 (pt)
JP (4) JP5813513B2 (pt)
KR (2) KR101801213B1 (pt)
CN (2) CN102307591B (pt)
AU (1) AU2009333484B2 (pt)
BR (1) BRPI0922867B8 (pt)
CA (1) CA2746228C (pt)
CY (2) CY1117757T1 (pt)
DK (2) DK2370099T3 (pt)
ES (3) ES2582005T3 (pt)
HR (2) HRP20160859T1 (pt)
HU (2) HUE029037T2 (pt)
IL (2) IL213450B (pt)
LT (1) LT3067064T (pt)
MX (4) MX345700B (pt)
PL (2) PL3067064T3 (pt)
PT (2) PT2370099T (pt)
RU (1) RU2531510C2 (pt)
SG (2) SG172022A1 (pt)
SI (2) SI3067064T1 (pt)
SM (1) SMT202000411T1 (pt)
WO (1) WO2010077717A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
CA2743012A1 (en) * 2008-11-18 2010-05-27 Ligocyte Pharmaceuticals, Inc. Rsv f vlps and methods of manufacture and use thereof
EP3718566B1 (en) 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011046925A1 (en) * 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
US9724405B2 (en) 2010-11-05 2017-08-08 Novavax, Inc. Rabies glycoprotein virus-like particles (VLPS)
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
PL2707385T3 (pl) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Prefuzyjne antygeny RSV F
WO2013019800A1 (en) * 2011-08-01 2013-02-07 Emory University Vlps containing ligands and methods related thereto
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
EP2760469A4 (en) * 2011-09-30 2015-03-18 Novavax Inc RECOMBINANT RSV-F NANOPARTICLE VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
CN109266622B (zh) * 2012-08-01 2023-05-09 巴法里安诺迪克有限公司 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
RU2015138530A (ru) * 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
CN105189756B (zh) * 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
RU2685185C2 (ru) 2013-09-19 2019-04-16 Новавакс, Инк. Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
CN106795513B (zh) * 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
EA201892250A1 (ru) * 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
PH12022552125A1 (en) * 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
IL269534B2 (en) * 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
MX2019014719A (es) 2017-06-14 2020-08-03 Virometix Ag Peptidos ciclicos para proteccion contra el virus sincitial respiratorio.
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
KR20250067954A (ko) 2018-02-28 2025-05-15 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
AU2019238171B2 (en) 2018-03-19 2026-01-08 Novavax, Inc. Multivalent influenza nanoparticle vaccines
WO2019191623A1 (en) * 2018-03-30 2019-10-03 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (rsv) vaccines
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3873517A4 (en) 2018-10-29 2022-09-28 Emory University RSV VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
KR102725189B1 (ko) 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
AU2019408048A1 (en) 2018-12-20 2021-06-24 Universität Zürich Lipopeptide building blocks and synthetic virus-like particles
AU2020222962A1 (en) * 2019-02-11 2021-09-02 Children's Healthcare Of Atlanta, Inc. Chimeric RSV and hMPV F proteins, immunogenic compositions, and methods of use
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN115720581A (zh) * 2020-01-27 2023-02-28 诺瓦瓦克斯股份有限公司 冠状病毒疫苗配制品
CN115811986A (zh) 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
US20240076320A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
CN115927751B (zh) * 2022-09-17 2024-12-20 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
EP4644550A1 (en) * 2023-03-17 2025-11-05 WestVac Biopharma Co., Ltd. Vaccine against respiratory syncytial virus infection
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
CN119504955A (zh) * 2023-08-25 2025-02-25 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸及疫苗
WO2025051250A1 (zh) * 2023-09-07 2025-03-13 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
WO2025101668A1 (en) 2023-11-06 2025-05-15 Novavax, Inc. Intranasal immunogenic compositions
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560B (zh) * 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN119161422A (zh) * 2024-08-26 2024-12-20 扬州大学 一种呼吸道合胞病毒融合前f蛋白及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU769992B2 (en) 1998-12-17 2004-02-12 Aventis Pasteur Limited Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AU1591402A (en) 2000-10-02 2002-04-15 Smithkline Beecham Biolog Vaccine
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2004273776B2 (en) 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2529710A1 (en) * 2003-06-20 2005-03-10 Protein Sciences Corporation Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US7588770B2 (en) 2003-12-10 2009-09-15 The Uab Research Foundation Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins
US8846607B2 (en) 2004-10-29 2014-09-30 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
EP1869225A4 (en) 2005-03-10 2010-02-24 Medimmune Vaccines Inc METAPNEUMOVIRENSTÄMME AND THEIR USE IN VACCINATE FORMULATIONS AND AS VECTORS FOR THE EXPRESSION OF ANTIGENOUS SEQUENCES AND METHOD FOR SPREADING THE VIRUS
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007149490A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP2099486A2 (en) 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
ES2542644T3 (es) 2007-07-19 2015-08-07 Novavax, Inc. VLPS quiméricas de la gripe aviar
EP2207558A1 (en) 2007-11-06 2010-07-21 Massachusetts Institute of Technology Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair
MX2010007107A (es) 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Antigenos de virus del sincicio respiratorio recombinantes.
EP2254554A1 (en) 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
EP3718566B1 (en) 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CA2762650A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CA2766211A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US9724405B2 (en) 2010-11-05 2017-08-08 Novavax, Inc. Rabies glycoprotein virus-like particles (VLPS)
CN102107003A (zh) 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
JP2014520807A (ja) * 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
EP2760469A4 (en) 2011-09-30 2015-03-18 Novavax Inc RECOMBINANT RSV-F NANOPARTICLE VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
RU2015138530A (ru) 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity

Also Published As

Publication number Publication date
JP2015171378A (ja) 2015-10-01
SI2370099T1 (sl) 2016-08-31
LT3067064T (lt) 2020-09-10
US10022437B2 (en) 2018-07-17
EP2370099A1 (en) 2011-10-05
ES2796725T3 (es) 2020-11-30
US9675685B2 (en) 2017-06-13
EP3067064B1 (en) 2020-05-13
ES2987238T3 (es) 2024-11-14
SMT202000411T1 (it) 2020-09-10
MX358836B (es) 2018-09-05
HUE029037T2 (en) 2017-01-30
US20230293667A1 (en) 2023-09-21
US20190134187A1 (en) 2019-05-09
CN102307591A (zh) 2012-01-04
CA2746228A1 (en) 2010-07-08
US8715692B2 (en) 2014-05-06
HK1161690A1 (zh) 2012-08-03
PL3067064T3 (pl) 2020-11-02
EP3718566B1 (en) 2024-06-12
KR20160148720A (ko) 2016-12-26
AU2009333484A1 (en) 2011-07-21
US20140294879A1 (en) 2014-10-02
WO2010077717A1 (en) 2010-07-08
KR20110112328A (ko) 2011-10-12
SI3067064T1 (sl) 2020-09-30
RU2011128371A (ru) 2013-01-20
PL2370099T3 (pl) 2016-10-31
US20150359872A1 (en) 2015-12-17
IL247341B (en) 2018-04-30
BRPI0922867B1 (pt) 2020-09-29
CA2746228C (en) 2021-05-18
EP2370099B1 (en) 2016-04-20
CY1117757T1 (el) 2017-05-17
ES2582005T3 (es) 2016-09-08
US12357684B2 (en) 2025-07-15
MX337932B (es) 2016-03-28
DK3067064T3 (da) 2020-06-08
HRP20200871T1 (hr) 2020-10-30
US9717786B2 (en) 2017-08-01
BRPI0922867A2 (pt) 2016-09-27
HRP20160859T1 (hr) 2016-09-23
PT2370099T (pt) 2016-07-14
JP2019069982A (ja) 2019-05-09
MX345700B (es) 2017-02-10
DK2370099T3 (en) 2016-08-01
CN106146671B (zh) 2020-03-31
US20100239617A1 (en) 2010-09-23
AU2009333484B2 (en) 2014-12-11
JP2012511579A (ja) 2012-05-24
IL213450B (en) 2018-02-28
US9731000B2 (en) 2017-08-15
CN102307591B (zh) 2016-08-03
US20150265698A1 (en) 2015-09-24
JP6462048B2 (ja) 2019-01-30
JP6162751B2 (ja) 2017-07-12
EP3718566A1 (en) 2020-10-07
IL213450A0 (en) 2011-07-31
RU2531510C2 (ru) 2014-10-20
JP6782289B2 (ja) 2020-11-11
JP5813513B2 (ja) 2015-11-17
US20150266930A1 (en) 2015-09-24
EP2370099A4 (en) 2013-05-29
JP2018007655A (ja) 2018-01-18
CN106146671A (zh) 2016-11-23
SG172022A1 (en) 2011-07-28
EP3067064A1 (en) 2016-09-14
SG10201500161XA (en) 2015-03-30
US11052146B2 (en) 2021-07-06
KR101691574B1 (ko) 2017-01-02
CY1123152T1 (el) 2021-10-29
KR101801213B1 (ko) 2017-11-24
PT3067064T (pt) 2020-06-16
HUE051666T2 (hu) 2021-03-29
MX2011006205A (es) 2011-09-01

Similar Documents

Publication Publication Date Title
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
MX2012000036A (es) Vacuna.
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
BR112014007616A2 (pt) vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
DE602006019629D1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EA201070794A1 (ru) Рекомбинантные антигены rsv
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
BR112015008930A2 (pt) vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
ATE538810T1 (de) Funktionale influenza-virus-ähnliche teilchen (vlps)
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
BR112013000996A2 (pt) proteína l1 hpv58 truncada ou variante da mesma, ácido nucleíco isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada por infecção hpv, e uso da proteína l1 hpv58 truncada ou variante da mesma
WO2012040266A3 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
WO2012167139A3 (en) Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
AR077398A2 (es) Particulas similares a virus de hpv31 (virus del papiloma humano). metodo para producirlas, vacuna y composicion que las contienen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF